BriaCell (BCTX) Therapeutics announces a collaboration with Memorial Sloan Kettering Cancer Center’s, MSK’s, Therapeutics Accelerator Cohort program to accelerate the clinical development of Bria-OTS+, BriaCell’s next generation personalized off-the-shelf immunotherapy, for multiple cancer indications including metastatic breast cancer, prostate cancer, and other cancers. The collaboration starts with manufacturing, IND development and clinical protocol support for a Phase 1 clinical trial with Bria-BRES+, BriaCell’s next generation personalized immunotherapy for patients with breast cancer under the Bria-OTS+ platform. The partnership expands on BriaCell’s previously-announced selection into MSK’s accelerator program.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BCTX:
- BriaCell Reports Promising Phase 3 Data in Metastatic Breast Cancer Study
- BriaCell presents Phase 3 clinical biomarker data at ESMO 2025
- Promising Phase 3 Results for BriaCell’s Bria-IMT in Metastatic Breast Cancer
- BriaCell Reports Positive Phase 3 Biomarker Data for Metastatic Breast Cancer Treatment
- BriaCell to present clinical biomarker data of Phase 3 Bria-IMT study